Pegasus Asset Management Inc. Reduces Stake in MiMedx Group, Inc. (NASDAQ:MDXG)

Pegasus Asset Management Inc. lessened its position in shares of MiMedx Group, Inc. (NASDAQ:MDXG) by 4.2% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 160,000 shares of the company’s stock after selling 7,000 shares during the quarter. Pegasus Asset Management Inc. owned approximately 0.11% of MiMedx Group worth $1,539,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in MDXG. Allspring Global Investments Holdings LLC grew its stake in MiMedx Group by 1.0% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 183,021 shares of the company’s stock worth $1,082,000 after acquiring an additional 1,822 shares during the period. Disciplined Growth Investors Inc. MN raised its position in shares of MiMedx Group by 0.8% in the 3rd quarter. Disciplined Growth Investors Inc. MN now owns 355,387 shares of the company’s stock worth $2,100,000 after buying an additional 2,737 shares during the period. SkyView Investment Advisors LLC raised its holdings in shares of MiMedx Group by 30.0% in the 3rd quarter. SkyView Investment Advisors LLC now owns 13,000 shares of the company’s stock worth $77,000 after purchasing an additional 3,000 shares during the period. Principal Financial Group Inc. increased its position in MiMedx Group by 6.3% during the 3rd quarter. Principal Financial Group Inc. now owns 55,495 shares of the company’s stock worth $328,000 after purchasing an additional 3,292 shares in the last quarter. Finally, Orion Capital Management LLC raised its stake in shares of MiMedx Group by 46.3% in the 3rd quarter. Orion Capital Management LLC now owns 11,700 shares of the company’s stock valued at $69,000 after acquiring an additional 3,700 shares during the period. 79.15% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, StockNews.com lowered MiMedx Group from a “strong-buy” rating to a “buy” rating in a research report on Friday, November 8th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, MiMedx Group has an average rating of “Buy” and an average price target of $12.00.

MiMedx Group Price Performance

Shares of MDXG opened at $8.22 on Wednesday. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.10 and a quick ratio of 3.53. The stock has a fifty day moving average price of $8.92 and a 200 day moving average price of $7.62. The company has a market cap of $1.21 billion, a P/E ratio of 14.95 and a beta of 1.94. MiMedx Group, Inc. has a 12 month low of $5.47 and a 12 month high of $10.14.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.